Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback